Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.08 is 91% above its 3-year average of 0.04, around the middle of its 3-year range (-0.10–0.19).
As of the fiscal period ended Tuesday, June 30, 2026. 9.30% below its 12-month average of 0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.08.
DEBT TO EQUITY RATIO
0.08
DEBT TO EQUITY RATIO AVG TTM
0.09
DEBT TO EQUITY RATIO AVG 3Y
0.05
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-9.30%
CURRENT VS 3Y AVG
+77.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-26.76%
vs the sector median at left
Market Cap
$830.99M
Debt to Equity Ratio
0.03
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$840.51M
Debt to Equity Ratio
0.01
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$828.59M
Debt to Equity Ratio
0.08
TTM Avg
0.18
3Y Avg
0.20
5Y Avg
0.16
Market Cap
$851.61M
Debt to Equity Ratio
N/A
TTM Avg
71.70
3Y Avg
36.60
5Y Avg
24.63
Market Cap
$852.92M
Debt to Equity Ratio
1.73
TTM Avg
1.19
3Y Avg
0.87
5Y Avg
0.60
Market Cap
$858.31M
Debt to Equity Ratio
0.09
TTM Avg
9.19
3Y Avg
9.19
5Y Avg
5.13
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $831.93M | 0.08 | 0.09 | 0.05 | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $830.99M | 0.03 | 0.07 | 0.07 | 0.07 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.51M | 0.01 | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $828.59M | 0.08 | 0.18 | 0.20 | 0.16 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $851.61M | N/A | 71.70 | 36.60 | 24.63 |
| QuidelOrtho Corporation (QDEL)vs › | $852.92M | 1.73 | 1.19 | 0.87 | 0.60 |
| SI-BONE, Inc. (SIBN)vs › | $856.16M | 0.04 | 0.12 | 0.21 | 0.23 |
| Ardelyx, Inc. (ARDX)vs › | $812.58M | 1.72 | 1.08 | 0.72 | 0.64 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $858.31M | 0.09 | 9.19 | 9.19 | 5.13 |
| Jade Biosciences, Inc. (JBIO)vs › | $806.39M | 0.00 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.08
Current Ratio
6.74
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.08 |
| 2026-03-31 | 0.06 |
| 2025-12-31 | 0.12 |
| 2025-09-30 | 0.10 |
| 2025-06-30 | 0.08 |
| 2025-03-31 | 0.19 |
| 2024-12-31 | 0.12 |
| 2024-09-30 | 0.09 |
| 2024-06-30 | -0.07 |
| 2024-03-31 | -0.08 |
| 2023-12-31 | -0.10 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
